CN101623528B - 蒸发化合物的方法和装置 - Google Patents
蒸发化合物的方法和装置 Download PDFInfo
- Publication number
- CN101623528B CN101623528B CN2009101667825A CN200910166782A CN101623528B CN 101623528 B CN101623528 B CN 101623528B CN 2009101667825 A CN2009101667825 A CN 2009101667825A CN 200910166782 A CN200910166782 A CN 200910166782A CN 101623528 B CN101623528 B CN 101623528B
- Authority
- CN
- China
- Prior art keywords
- drug
- matrix
- substrate
- housing
- flammable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 150000001875 compounds Chemical class 0.000 title claims description 9
- 230000008016 vaporization Effects 0.000 title claims description 4
- 239000003814 drug Substances 0.000 claims abstract description 78
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 239000000758 substrate Substances 0.000 claims abstract description 37
- 230000000977 initiatory effect Effects 0.000 claims abstract 2
- 239000011159 matrix material Substances 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000443 aerosol Substances 0.000 claims description 15
- 229910052782 aluminium Inorganic materials 0.000 claims description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 239000011521 glass Substances 0.000 claims description 13
- 238000002485 combustion reaction Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 238000002664 inhalation therapy Methods 0.000 abstract description 2
- -1 but not limited to Polymers 0.000 description 47
- 239000000446 fuel Substances 0.000 description 32
- 238000000576 coating method Methods 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000003575 carbonaceous material Substances 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 229960004193 dextropropoxyphene Drugs 0.000 description 3
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 3
- 238000009713 electroplating Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229960003941 orphenadrine Drugs 0.000 description 3
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 3
- 229960003910 promethazine Drugs 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 210000002268 wool Anatomy 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960003036 amisulpride Drugs 0.000 description 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 2
- 229950001647 clometacin Drugs 0.000 description 2
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960000299 mazindol Drugs 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 229960002601 protriptyline Drugs 0.000 description 2
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 2
- 229960003904 triflupromazine Drugs 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- ACEYAMOAGUDVAQ-UHFFFAOYSA-N 2-bromo-2-ethylbutanamide Chemical compound CCC(Br)(CC)C(N)=O ACEYAMOAGUDVAQ-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- PJAGGJPKGNYFJH-QGZVFWFLSA-N [(6ar)-11-acetyloxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10-yl] acetate Chemical compound C([C@H]1N(C)CC2)C3=CC=C(OC(C)=O)C(OC(C)=O)=C3C3=C1C2=CC=C3 PJAGGJPKGNYFJH-QGZVFWFLSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 description 1
- 229950004361 allylprodine Drugs 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229950008930 amfenac Drugs 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- ZVSGUZQJNXHNIL-UHFFFAOYSA-N amphenidone Chemical compound NC1=CC=CC(N2C(C=CC=C2)=O)=C1 ZVSGUZQJNXHNIL-UHFFFAOYSA-N 0.000 description 1
- 229950008169 amphenidone Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960002452 budipine Drugs 0.000 description 1
- QIHLUZAFSSMXHQ-UHFFFAOYSA-N budipine Chemical compound C1CN(C(C)(C)C)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 QIHLUZAFSSMXHQ-UHFFFAOYSA-N 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- ONAOIDNSINNZOA-UHFFFAOYSA-N chloral betaine Chemical compound OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O ONAOIDNSINNZOA-UHFFFAOYSA-N 0.000 description 1
- 229940118803 chloral betaine Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- QZXCCPZJCKEPSA-UHFFFAOYSA-N chlorfenac Chemical compound OC(=O)CC1=C(Cl)C=CC(Cl)=C1Cl QZXCCPZJCKEPSA-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- 229960001184 clopenthixol Drugs 0.000 description 1
- 229960003864 clotiapine Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229960003218 dolasetron mesylate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 238000007496 glass forming Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 description 1
- 229960003046 isometheptene Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 lofentanil Drugs 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 229950001846 mabuprofen Drugs 0.000 description 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 1
- 229950004211 nisoxetine Drugs 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960004505 penfluridol Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960000897 phenazocine Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- ZQHYKVKNPWDQSL-UHFFFAOYSA-N prinadol Chemical compound CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-UHFFFAOYSA-N 0.000 description 1
- 229960005253 procyclidine Drugs 0.000 description 1
- 229960002934 propentofylline Drugs 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229920003179 starch-based polymer Polymers 0.000 description 1
- 239000004628 starch-based polymer Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- QTFFGPOXNNGTGZ-RCSCTSIBSA-N u3c8e5bwkr Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(OC3C[C@@H]4CC5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-RCSCTSIBSA-N 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/60—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/047—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters by exothermic chemical reaction
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F24—HEATING; RANGES; VENTILATING
- F24V—COLLECTION, PRODUCTION OR USE OF HEAT NOT OTHERWISE PROVIDED FOR
- F24V30/00—Apparatus or devices using heat produced by exothermal chemical reactions other than combustion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8268—Fuel storage cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Combustion & Propulsion (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catching Or Destruction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
Abstract
本发明公开了一种快速加热涂布物质的方法和设备,所述物质优选包括一种待蒸发用于吸入疗法的药物。本发明的设备(10)优选包括基质(20),它有包围内部区域的内表面(20a)和涂布物质(15)粘附其上的外表面(20b)。尽管基质优选是金属的,但是它不一定是金属的。将易燃成分(16a,16b)放置在基质的内部区域并将火花或电阻点火器与易燃成分相连。该点火器用于引发易燃成分氧化。优选,该涂布物质在外壳(30)内蒸发使得蒸发的药物能够气溶胶化并被使用者吸入。
Description
本申请是2003年5月13日提交的,申请号为03814156.6,发明题目为“蒸发化合物的方法和装置”的分案申请。
发明领域
本发明涉及通过吸入途经递送气溶胶的方法和设备。具体地说,本发明涉及一种制备含有用于吸入疗法的活性药物的气溶胶的方法和设备。
发明背景
已知将药物气溶胶化用于通过吸入递送。例如,Clearman等人的美国专利5,099,861针对气溶胶递送物(“Clearman等人”)公开了一种设备,它包括载有风味剂或药物的基质。该基质经燃烧燃料成分而受热,所述燃料成分可以是“挤出的碳质材料”。加热基质使得风味剂或药物气溶胶化,这样使用者能够吸入该风味剂或药物。然而,由于Clearman等人公开的设备燃烧碳质材料产生热量,因此加热和气溶胶的产生相当慢。此外,使用者必需使用单独的器具,例如引燃器或火柴,以点燃该燃料成分。同样,该燃料成分可能产生不希望的产物如异味和烟雾,它们可能刺激使用者或旁观者。Clearman等人的设备的这些缺点可能使得该设备相当不方便。
Katsuda等人的美国专利4,693,868针对药物的热烟熏器(“Katsuda等人”)也公开了一种设备,该设备可用于蒸发药物进行吸入递送。正如Clearman等人的,Katsuda等人也使用热量蒸发药物。然而Katsuda等人公开了点燃挥发性燃料例如醇、石油或醚以产生引起药物蒸发所需的热量。挥发性燃料装在容器内并由装在设备内的金属催化剂点燃。然而,尽管Katsuda公开的燃料的燃烧通常比Clearman等人公开的碳质材料燃料的燃烧快得多,但是Katsuda等人公开的燃料的点燃仍然会相对慢。此外,Katsuda等人公开的燃料在燃烧之后产生气体产物。因此,如果燃料装在密封容器中,容器内的压力可能会增加并引起破裂。此外,即使提供阀以便燃烧时溢出过量气体,然而溢出的气体可能产生令人不快的异味。
发明概述
本发明提供了一种方法和装置,它用于从自给单元提供药物的吸入递送。本发明的方法和设备能够快速加热涂布的药物产生蒸汽。快速加热之后进行冷却并将蒸汽冷凝成气溶胶,也称之为冷凝气溶胶,它可以被使用者吸入从而递送计量的药物。本发明的方法和装置通过使用具有易燃成分的密封燃料电池来获得这种快速加热。由于该燃料电池经密封,因此有益地不会使令人不快的燃烧产物释放到周围环境中。此外,该成分燃烧相当快并优选不产生引起密封的燃料电池内压力增加的的气体产物。
本发明的快速加热涂布物质的设备优选包括一基质,它有一包围内部区域的内表面和一涂布物质粘附其上的外表面。尽管基质优选是金属的,但是它不一定是金属的。易燃成分放置在基质的内部区域并且一点火器与易燃成分相连。该点火器用于引发易燃成分氧化。优选,该涂布物质包含在外壳内蒸发的药物从而能够使蒸发的药物被使用者吸入。
附图简述
图1是显示用于蒸发药物、包括密封的燃料电池的本发明设备的内部细节的侧视图。
图2是显示图1所示设备的远侧部的内部细节的顶视图。
图3是显示图1所示设备的远侧部的外表面的透视图。
图4是显示图1所示设备的外表面的透视图。
图5是图1所示设备的详细侧剖视图。
图6是描述本发明经吸入递送药物的方法的流程图。
图7是可与本发明的图1所示外壳一起使用的密封燃料电池和基质的另一实施方式的侧视图。
图8是可与本发明的图1所示外壳一起使用的密封燃料电池和基质的另一实施方式的侧视图。
优选实施方式的详述
本文所用的术语“气溶胶”是指固体或液体颗粒在气体中的混悬液,并且术语“蒸汽”是指气体,“蒸汽相”是指气相,术语“热蒸汽”是指蒸汽相、气溶胶或气溶胶-蒸汽相的混合物,优选经加热形成。
图1是显示本发明的药物递送设备10的优选实施方式的内部构造的侧视图,它使用放热反应迅速加热药物。药物递送设备10包括燃料电池12,它用于包括基质20包围的放热反应,所述基质涂布有药物15或含有药物的化合物。在图1所示的实施方式中,燃料电池12和基质20被外壳30包围,所述外壳有远端部分30a、近端部分30b并包括气道32和接口34。气道32提供了气溶胶化的药物从外壳30的中部到接口34的路径,它便于气溶胶化的药物的吸入。优选,药物递送设备10包括两个部分;近端部分30b和远端部分30a,它们可以沿分界线90彼此分开,该分界线将在下面更详细地讨论。
在图1所示的实施方式中,燃料电池12包括两个密封的球形物(bulb)14a和14b,它们分别含有易燃成分16a和16b。尽管图1显示了两个球形物14a和14b,但是也可以认为仅包括一个在燃料电池12中含有单一燃料成分的球形物。燃料电池12基本上可以包括照相中仍然使用类型的标准闪光球形物或单个标准闪光球形物。优选,每个球形物14a、14b内的环境可以含有相对高百分比的氧;优选60%-100%氧,更优选75%-95%氧。优选球形物14a和14b内的压力大于大气压,更优选该压力在5-10大气压之间。球形物14a和14b优选由玻璃形成,并且可以,但不一定,在外表面涂布有聚合物(图1中未显示),如果在燃料电池12点燃时玻璃破碎的话,该聚合物可以含有玻璃颗粒。这种聚合物涂层可以包括,但不限于,各种漆(laquers)、乙酸纤维素、聚酰胺类或Teflon 优选,这种聚合物涂层的厚度在0.01mm-1.0mm之间。适用于本发明方法和装置的球形物几十年来一直可作为生产的工业品商购自主要的球形物供应商,这些供应商例如有Osram Sylvania of Danvers,MA(商品名BlueDot 闪光球形物)、General Electric和Philips Corporation。用于玻璃球形物例如球形物14a和14b的聚合物涂层的形成在本领域为已知,并且例如公开在Fonda等人的美国专利4,198,200(防伤害的涂层),将其全 文加入本文作为参考。
易燃成分16a和16b分别包含在密封的球形物14a和14b中。优选,易燃成分16a和16b包括由易燃金属例如铝、镁或锆形成的细丝,这些金属形成为本领域技术人员理解的“羊毛”丝条。然而,易燃成分16a和16b可以由任意易燃细丝例如,但不限于,诸如浸润易燃金属的细丝形成。
在图1所示的实施方式中,易燃成分16a暴露于一组金属电极18a和18b下,通过它将涂布引发剂的电阻成分连起来,并且它穿过球形物14a凸出并与如下所述的点燃电源40相连。电极18a和18b优选由铜形成,但是可以由任意的导电材料例如,但不限于,铝形成。电源40优选是相对小的、可携带的电源例如,但不限于干电池。如果使用干电池作为电源40,那么电池的电压优选在1.5-9伏之间。电极18a和18b与电源40通过下面所述的导线21a和21b相连。
正如从图2中可以看到的,它是显示内部结构的外壳30的远端部分30a的顶视图,电源40优选包括两个1.5伏的干电池40a和40b。应理解为可以将其它类型的电源与本发明的药物递送设备一起使用,它们包括,但不限于,标准9v电池。电池40a和40b优选经电极60和62串连。电极62优选是一基本上平的板,它位于外壳30的远端部分30a的基底31与电池40a和40b之间。电极60优选包括移动部分60a,它与电池40a接触并经缝隙60c与静态部分60b分开,静态部分与电池40b接触。移动部分60a和静态部分60b彼此形成为钩状并由弹性导电材料制成以便部分60a可以弹性地变形以闭合移动部分60a和静态部分60b之间的缝隙60c,从而闭合包括电池40a和40b的串联电路。
图3是外壳30的远端部分30a的外部的透视图。正如所示的,远端部分30a包括与基底31相邻的上面凹口72以及与上面凹口72相对并且也与基底31相邻的下面凹口70。如图1和/或3所示,电极62在外壳30的远端部分30a上的上面凹口72延伸通过外壳30,电极60在下面凹口70延伸通过外壳30。
如图5所示,它是显示设备10的一部分附近的细节的药物递送设备10的截面侧视图,其中它分成2个部分,外壳30包括上面鳍状部分82 和下面鳍状部分80,它们分别与上面凹口72和下面凹口70相互连接,如图3所示。上面鳍状部分82包括连接电极86,当远端部分30a与近端部分30b啮合时该连接电极与电极62接触。此外,下面鳍状部分80包括连接电极84,当远端部分30a与近端部分30b啮合时它与电极60接触。电极18a优选与电极62通过连接电极86相连,并且电极18b优选与电极60通过连接电极84相连。再次参照图2,在所示的实施方式中,设备10包括按钮63,它与电极60的移动部分60a的平坦部分接触。按钮63可以由使用者压下以闭合包括电池40a和40b的电路并分别给电极60和62提供能量。在燃料电池的另一实施方式中,易燃成分可以被压电结晶(或磷光体)点燃,其接着引起放出(或被点燃)机械撞针。
再次参见图1,如上所述,密封的球形物14a和14b内的环境优选包括高百分比的氧。因此,如果易燃成分16a和16b包括易燃金属例如镁或锆,那么由电源40提供电压,使得易燃成分16a点燃并快速氧化。因易燃成分16a燃烧发出的热和光使得共鸣地点燃易燃成分16b。成分16a和16b的放热燃烧向周围环境和基质20放出热。优选,每个易燃成分16a、16b由约1mMol金属羊毛制成。使用这种量的羊毛,该放热反应典型地耗时20-30毫秒。该放热反应向基质20提供的热量使得涂布在基质20上的药物蒸发。如上所述,由于易燃成分16a和16b的燃烧分别发生在密封的球形物14a和14b中,因此没有令人不快的燃烧产物逃逸到周围环境中。此外,金属的氧化,例如在易燃成分16a和16b燃烧时发生,因此不产生气体产物。这样,球形物14a和14b内的压力不会过度增加超过易燃成分16a和16b氧化之后因温度升高引起的增加。
基质20优选形成为基本上圆柱形鞘,它在该圆柱体的一端有开口从而使得球形物14a和14b能够插入。圆柱形鞘的相对端优选封闭,但是也可以是开放的。形成基质20的圆柱形鞘优选围绕球形物14a和14b紧紧地固定。优选,基质20由铝杆加工形成约0.05mm-约0.15mm厚的圆柱体。基质20也可以经过延伸、捣磨,或者可以包括将铝片辊压或者使用铝箔的任意方式形成,并且可以是任何合适的厚度。如图1所示,基质20可以形成具有一个或多个增加厚度的部分25以增加基质20的硬度。 如果使用的话,增加厚度的部分25优选位于基质20未接触球形物14a和14b的区域。为了将球形物14a和14b牢固地固定在基质20内,基质20可以经过略微加热使圆柱体的直径膨胀。然后将球形物14a和14b放入基质20内,冷却后它将贴切地围绕球形物14a和14b固定。优选,球形物14a和14b直径为约1cm。这样,基质20的内径也接近1cm。
基质20沿其长度部分被支持在外壳30的内部在包围基质20的圆柱形套管37中。套管37优选与外壳30一起整体地形成并与外壳30在外壳30的正面近端部分30b的基底(图1上未显示)处相连。基质20可以使用已知的粘合剂或者简单地通过摩擦安装粘附到套管37内。套管37包括插座59,它支持图1的导线21a和21b,并且其中可以插入球形物14a的基底使电极18a和18b能够以已知的方式接触导线21a和21b。以这种方式,得自电源40的电力可以经导线21a和21b提供给易燃成分16a。基质20的相对端,离接口34最近的端,优选闭合并包括增加厚度的部分25。
包括基质20可以各种形状成型。例如,基质也可以是矩形盒的形状。优选,基质提供大的表面与体积比(例如,大于100/米)和大的表面与质量比(例如,大于1cm2/g)。此外,可以使用许多不同的材料构造基质。这些类型的材料包括,但不限于,金属、无机材料和聚合物。以下是这些材料类型的实例:铝、银、金、不锈钢、铜和钨;二氧化硅、玻璃、硅和钒土;石墨、多孔碳、碳丝和碳毡;聚四氟乙烯和聚乙二醇。也可以使用材料和涂布的材料变体的组合。二氧化硅、钒土和硅基材料的实例包括无定形二氧化硅S-5631(Sigma,St.Louis,MO)、BCR171(一种定义表面积大于2m2/g的钒土,得自Aldrich,St.Louis,MO)和半导体工业中使用的硅片。碳丝和毡得自American Kynol,Inc.,New York,NY。色谱树脂例如与多孔二氧化硅化学相连的十八烷基甲硅烷是例证的涂布的二氧化硅变体。
如图1所示,基质20包括内表面20a,它优选,但不一定,与球形物14a和14b的外部和外表面20b接触。如上所述,易燃成分16燃烧期间放出的热量被基质20吸收,从而使得涂布在基质20的外表面20b上的药物蒸发。为了提高基质20对热量的吸收。基质20的内表面20a优选经 阳极化或者另外涂布以产生相对黑的表面。
还设计基质可以涂布在球形物14a和14b上。如果球形物14a和14b不包括聚合物涂层,那么可以使用已知的蒸发或电镀工艺将基质直接涂布到球形物14a和14b的玻璃表面上。如果球形物14a和14b的确包括聚合物涂层,那么可以使用已知的蒸发或电镀工艺将基质涂布到聚合物涂层上。如果基质涂布到球形物14a和14b上,可以使用已知的蒸发或电镀工艺可用的上述任意材料例如,但不限于,铝或不锈钢来形成基质。
还认为图1中形式的基质20可省去,并且形成球形物的玻璃作为基质。在这种实施方式中,可以将药物直接涂布到球形物的玻璃上。图7是描述燃料电池212的实施方式的图,它包括直接涂布有药物215的密封的玻璃球形物214。在玻璃球形物214的内部是易燃成分216,它可以大致与图1中所示的易燃成分16相同。燃料电池212还包括电极218a和218b,它们可以大致与图1中所示的电极18a和18b相同。易燃成分216与电极218a和218b接触,这样如果电压通过电极218a和218b,易燃成分216将点燃。如果使用这种实施方式,球形物优选制得比使用单个金属基质例如基质20或者球形物涂布有聚合物涂层的要相对厚些。因此,可以使用耐热打击的玻璃,例如Pyrex 其厚度可以防止易燃成分216燃烧震裂。药物215优选涂布在球形物216的外部,如下将要讨论。
将药物浸渗到聚合物基质中并将该基质直接涂布到球形物上也在本发明的范围内。图8是描述燃料电池112的实施方式的图,它包括胶囊114,该胶囊包括被外部聚合物基质114a包围的内部玻璃球形物114b。在玻璃球形物114b的内部,可与图1中所示的易燃成分16a和16b大致相同的易燃成分116接触118a和118b(它们可以与图1中所示的接触18a和18b大致相同)。可以与其中使用燃料电池12相同的方式在图1中所示的外壳30内使用燃料电池112,只是不必要基质20。聚合物基质114a优选用药物浸渗之后使用。优选,基质例如聚合物基质114a厚度为0.01mm-1mm。可以通过将基质114a暴露于药物中将药物浸渗到聚合物基质114a中。例如,可以将燃料电池112浸泡在含有药物和溶剂的溶液中,或者仅含药物的溶液中,持续1小时以上。在这种实施方式中,基质可以 由聚酰胺或Teflon 或其它热稳定的聚合物形成。
图4是显示了外壳30的外表面的药物递送设备10的透视图(如图1所示)。如所示,外壳30优选形状为椭圆体,在与设备10的长轴横断的方向具有椭圆形横截面。正如上面讨论的,基质20和球形物14a和14b优选与外壳30牢固地连接以便基质20和球形物14a和14b以大致同心的方式悬挂在外壳30内。外壳30的近端部分30b优选包括接口34。此外,外壳30的上表面优选包括开口68a和68b,如图1所示,所述开口与气道32处于流体连接从而能够使空气从外壳30的外部进入气道32。外壳30的下表面优选也含有开口,它们在图4中看不到,与开口68a和68b相对。外壳30可以由各种聚合物形成,这些聚合物包括,但不限于,可生物降解的聚合物如可得自E.I.du pont de Nemours and Company的Biomax 或其它淀粉基聚合物。外壳30可以通过注塑上半区和下半区并将这两半以本领域公知方法装配成型。优选,但不一定,横断设备10的长轴方向的外壳30的椭圆形横截面在短轴方向具有约2cm的内径并在长轴方向具有约3cm的内径。还认为外壳30可以任意其它大小或形状,例如,但不限于,圆柱体、矩形盒、三角形盒或其它形状成型。
如上所述,外壳30的近端部分30b可以与外壳30的远端部分30a分离。如图1所示并如上面讨论的,远端部分30a包括电源40和启动按钮63用于药物递送设备10。并且,近端部分30b包含球形物14a、14b和涂布有待递送的药物的基质20。因此,近端部分30b在食用包含在近端部分30b内的剂量时可以从远端部分30a拆下,之后扔掉。远端部分30a,包括电源40,然后可以与含有新鲜剂量的涂布的药物的另一近端部分重新使用。远端部分30a以这种方式可以有益地使用许多次直到电源40耗尽。部分30a和30b可以,如本领域理解的,经模制咬合、扭-锁或者以其它方式连接在一起成为剂量形式的气溶胶化的制剂。
涂布在基质20上的药物的气溶胶化上通过将按钮63压下以闭合电源40与易燃成分16a之间的连接实现的。当电源40向易燃成分16a施加一电压时它被点燃。如上所述,易燃成分16a优选是易燃金属,它在燃料电池12的环境下快速氧化。氧化优选包括在燃料电池12内的这些易燃金属 通常花费20-30毫秒并将释放约800焦耳-约900焦耳的能量。释放该能量将使得基质20的外表面20b的温度升高至约350℃-约600℃。这通常足以使在基质20的外表面20b的药物蒸发。优选,药物蒸汽然后在气道32内冷却形成气溶胶。优选,气溶胶化的药物的粒径范围从约1μm-约3μm。为了接收剂量的气溶胶化药物,使用者将接口34对着使用者的口,通过压按钮63激活,并吸入。空气将流过外壳30的开口,通过气道32并进入接口34,这样气溶胶化药物可以进入使用者的肺中。
图6描述了根据本发明经吸入递送药物的方法300。在步骤310中提供基质,例如图1中所示的基质20,它可以支持待加热和蒸发的药物,正如上面讨论的。基质优选经成型包括内部区域和外表面。在步骤312中,药物优选涂布到基质的外表面,正如下面讨论的。在步骤314中,至少一个密封的球形物,例如图1中所示的球形物14a,放置在基质的内部区域。正如上面讨论的,密封的球形物优选含有易燃细丝,它包括易燃金属,例如铝、锆或镁。易燃细丝优选与两个延伸到球形物外面并且可以与电源间歇地连接的电极电连接,例如图1中所示的电源40,从而能够点燃易燃成分。在步骤316中,电极转换成电源电路并将易燃成分点燃。该点燃发出放热反应,从而将基质加热并将涂布其上的药物蒸发,正如上面讨论的。在步骤318中,使药物冷却形成气溶胶。优选该冷却是在气道中进行的,例如图1中所示的气道32,它包围基质的外表面。在步骤320中,气溶胶化的药物被使用者吸入。在另一实施方式中,在步骤312中,不是在步骤310中提供的将药物涂布到基质的外部,考虑用待气溶胶化的药物浸渗基质,如上面讨论的。
如上所述,本发明的形成气溶胶的设备将药物快速加热产生蒸汽,之后将该蒸汽冷却并将蒸汽冷凝得到气溶胶,也称之为冷凝气溶胶。该药物组合物优选以两种形式之一受热:以纯的活性化合物或活性化合物与药用可接受的赋形剂的混合物。
本文使用的术语“药物”是指任意的化合物,它可用于预防、诊断、治疗或治愈疾病,用于缓解疼痛,或者控制或改善任何人或动物的任何生理或病理紊乱。药物的类型包括,但不限于,如下:抗生素类、抗惊厥剂、 抗抑郁药、止吐药、抗组胺剂、抗震颤麻痹药、抗精神病药、抗焦虑剂、勃起机能障碍用的药物、偏头痛用的药物、治疗酒精中毒用的药物、肌松药、非甾体抗炎剂、鸦片类、其它镇痛药、兴奋药和类固醇。
抗生素类的实例包括头孢美唑、头孢唑啉、头孢菌素、头孢西丁、头孢乙氰、头孢菌素III、头孢利素、头孢菌素c、cephalotin、头霉素a、头霉素b、头霉素c、cepharin、头孢霉定、氨苄西林、阿莫西林、海他西林、卡非西林、卡茚西林、羧苄西林、戊青霉素、阿度西林、苄青霉素、氯甲西林、氯唑西林、环青霉素、甲氧西林、萘夫西林、2-戊烯青霉素、青霉素n、青霉素o、青霉素s、青霉素v、氯丁青霉素、双氯西林、联苯青霉素、庚青霉素和美坦西林。
抗惊厥剂的实例包括4-氨基-3-羟基丁酸、乙二磺酸酯、加巴喷丁和氨己烯酸。
抗抑郁药的实例包括阿米替林、阿莫沙平、苯酰甲苄肼、布替林、氯米帕明、地昔帕明、度硫平、多塞平、丙米嗪、kitanserin、洛非帕明、美地沙明、米安色林、麦普替林、米氮平、去甲替林、普罗替林、曲米帕明、维洛沙秦、西酞普兰、可替宁、度洛西汀、氟西汀、氟伏沙明、米那普仑、尼索西汀、帕罗西汀、瑞波西汀、舍曲林、噻奈普汀、乙酰奋乃静(acetaphenazine)、苯奈达林、溴法罗明、西文氯胺、氯伏胺、异丙异烟肼、异卡波肼、吗氯贝胺、苯肼(phenyhydrazine)、苯乙肼、司来吉兰、西布曲明、反苯环丙胺、腺苷蛋氨酸、阿屈非尼、安麦角、氨磺必利、安哌齐特、贝那替秦、丁氨苯丙酮、卡罗沙酮、吉哌隆、咪唑克生、美曲吲哚、米那普仑、米那普令、奈法唑酮、诺米芬辛、利坦色林、罗克吲哚、S-腺苷蛋氨酸、托芬那辛、曲唑酮、色氨酸、文拉法辛和扎螺酮。
止吐药的实例包括阿立必利、阿扎司琼、苯喹胺、溴必利、布克力嗪、氯丙嗪、桂利嗪、氯波必利、塞克力嗪、苯海拉明、地芬尼多、多拉司琼甲磺酸盐、达哌啶醇、格拉司琼、东莨菪碱、劳拉西泮、甲氧氯普胺、美托哌丙嗪、昂丹司琼、奋乃静、异丙嗪、丙氯拉嗪、东莨菪碱、三乙膦、三氟拉嗪、三氟丙嗪、曲美苄胺、托烷司琼、domeridone和帕洛诺司琼。
抗组胺剂的实例包括阿扎他定、溴苯那敏、氯苯那敏、氯马司汀、塞 庚啶、右美托咪定、苯海拉明、多西拉敏、安他乐、塞替利嗪、非索非那定、loratidine和普鲁米近。
抗震颤麻痹药的实例包括金刚烷胺、巴氯芬、比哌立登、苯扎托品、奥芬那君、丙环定、苯海索、左旋多巴、卡比多巴、司来吉兰、塞利吉林、andropinirole、阿扑吗啡、苄丝肼、溴角麦环肽、布地品、卡麦角林、二氢麦角隐亭、依利罗地、依斯的明、麦角灵、雪花胺、拉扎贝胺、麦角乙脲、氯苯咪吲哚、美金刚、莫非吉兰、培高利特、普拉克索、丙戊茶碱、雷沙吉兰、瑞马西胺、spheramine、特麦角脲、恩他卡朋和托卡朋。
抗精神病药的实例包括醋奋乃静、阿立必利、安哌齐特、苯哌利多、苯喹胺、溴哌利多、布拉氨酯、布他哌嗪、丙酰奋乃静、卡匹帕明、氯丙嗪、氯葡噻吨、氯卡帕明、氯胺丙压吖、氯哌噻吨、氯螺旋嗪、氯噻平、氯美马嗪、达哌啶醇、三氟噻醇、氟奋乃静、氟司必林、氟哌啶醇、美索哒嗪、美托奋乃酯、molindrone、五氟利多、哌氰嗪、奋乃静、匹莫齐特、匹泮哌隆、哌西他嗪、哌泊噻嗪、丙氯拉嗪、丙嗪、瑞莫必利、舍吲哚、螺哌隆、舒必利、硫利达嗪、替沃噻吨、三氟哌多、三氟丙嗪、三氟拉嗪、齐拉西酮、佐替平、珠氯噻醇、氨磺必利、布他拉莫、氯氮平、美哌隆、奥氮平、喹硫平和利培酮。
抗焦虑剂的实例包括甲氯喹酮、美托咪定、美托咪酯、阿地唑仑、氯氮卓、氯苯西泮、氟西泮、劳拉西泮、氯普唑仑、咪达唑仑、阿吡坦、阿舍西隆、安非尼酮、阿扎环醇、溴米那、丁螺环酮、calciumN-carboamoylaspartate、卡普托胺、卡普脲、卡氯脲、卡溴脲、氯醛甜菜碱、恩西拉嗪、氟辛克生、伊沙匹隆、来索吡琼、洛沙平、甲喹酮、methprylon、心得安、坦度螺酮、曲口占诺、佐匹克隆和唑吡坦。
勃起机能障碍用药物的实例包括tadalafil(IC351)、昔多芬(sildenafil)、伐地那非、阿扑吗啡、阿扑吗啡二乙酸酯、酚妥拉明和育亨宾。
偏头痛用的药物的实例包括阿莫曲坦、alperopride、可待因、二氢麦角胺、麦角胺、依立曲坦、夫罗曲普坦、异美汀、利多卡因、麦角乙脲、甲氧氯普胺、那拉曲坦、羟考酮、丙氧酚、利扎曲坦、舒马普坦、托芬那 酸、佐米曲坦、阿米替林、阿替洛尔、可乐定、赛庚啶、地尔硫卓、多塞平、氟西汀、赖诺普利、美西麦角、美托洛尔、那多洛尔、去甲替林、帕罗西汀、苯噻啶、苯噻啶、心得安、普罗替林、舍曲林、噻吗洛尔和维拉帕米。
治疗酒精中毒用的药物的实例包括阿坎酸、纳洛酮、纳曲酮和双硫仑。
肌松药的实例包括巴氯芬、环苯扎林、奥芬那君、奎宁和替扎尼定。
非类固醇类消炎药的实例包括醋氯芬酸、阿氯芬酸、阿明洛芬、氨芬酸、氨丙吡酮、阿米西群、阿司匹林、苯噁洛芬、柏莫洛芬、溴芬酸、丁苯羟酸、布替布芬、bucloxate、卡洛芬、胆碱、辛可芬、桂美辛、环氯茚酸、clopriac、氯美辛、双氯芬酸、二氟尼柳、依托度酸、fenclozate、非诺洛芬、氟替阿嗪、氟比洛芬、布洛芬、异丁芬酸、消炎痛、吲哚洛芬、酮洛芬、酮洛酸、洛索洛芬、马泼尼酮、甲氯灭酸钠、奈普生、奥沙普秦、吡罗普康、吡洛芬、普罗度酸、水杨酸盐、双水杨酯、舒林酸、tofenamate和托美丁。
鸦片类的实例包括阿芬太尼、烯丙罗定、阿法罗定、阿尼利定、苄吗啡、贝齐米特、丁丙诺啡、布托啡诺、卡必芬、环丙法多、氯尼他秦、可待因、右马拉胺、右丙氧芬、海洛因、二氢可待因、地芬诺酯、地匹哌酮、芬太尼、氢吗啡酮、L-α乙酰基地美庚醇、洛芬太尼、左啡诺、哌替啶、美沙酮、美普他酚、美托酮、吗啡、纳布啡、烯丙吗啡、羟考酮、阿片全碱、哌替啶、喷他佐辛、非那佐辛、瑞芬太尼、舒芬太尼和曲马多。
其它镇痛药的实例包括阿扎丙宗、苄哌吡酮、benzydramine、丁丙二苯肼、氯美辛、氯尼辛、伊索庚嗪、氟吡丁、奈福泮、奥芬那君、丙帕他莫和右丙氧芬。
兴奋药的实例包括安非他命、马钱子碱、右芬氟拉明、右旋苯丙胺、麻黄素、苯氟拉明、氯苯咪吲哚、methyphenidate、匹莫林、芬特明和西布曲明。
类固醇的实例包括倍他米松、氯泼尼松、氯可托龙、肾上腺皮质素、地奈德、地塞米松、去羟米松、二氟泼尼酯、雌二醇、氟氢可的松、二氢美松、氟尼缩松、氟可龙、氟泼尼龙、氢化可的松、甲泼尼松、甲泼尼龙、 帕拉米松、泼尼松龙、泼尼松、孕烷-3-α-醇-20-酮、睾酮和曲安西龙。
药用可接受的赋形剂是挥发性的或非挥发性的。挥发性的赋形剂,当受热时,同时蒸发,气溶胶化并与待递送的药物一起吸入。这些赋形剂的类型在本领域为已知并且包括,但不限于,气态、超临界流体、液体和固体溶剂。如下是在这些类型内的例证载体的列表:水;萜类,例如薄荷醇;醇类,例如乙醇、丙二醇、甘油和其它类似的醇;二甲基甲酰胺;二甲基乙酰胺;蜡;及其混合物。
通常,用浸溃涂布法将药物涂布到本发明的基质上。在该方法中,首先制备药物溶液。溶液的溶剂这样选择,使得药物可以顺应涂布的浓度混溶其中。这种方法所用的典型溶剂包括,但不限于,二氯甲烷、醚、乙酸乙酯和甲醇。将基质在溶液中浸渍并以恒定速度取出。浸渍之后,将溶剂蒸发并通过基质加化合物的量减去基质的量计算涂布的药物量。该浸渍方法可以重复直到涂布所需量的药物。适用于实施本发明的方法和/或装置的浸渍涂布机可商购获得。一种这样的涂布机是DC-2000,它可从ConcoatLimited of Surry,England获得。
实施例
实施例1:从涂布聚合物的闪光球形物将药物气溶胶化
高能 闪光球形物,带有完整的聚合物涂层,经称重并放置在烟碱的小瓶中。使液体烟碱吸收到聚合物涂层中持续1小时,并用薄纸擦拭除去过量的液体。在氩气环境下使球形物在小瓶中平衡过夜。然后将小瓶打开并使氩气流过球形物持续45分钟。再称重,显示总共有24.6mg烟碱溶解在聚合物涂层中。将球形物包在一8mL小瓶中并通过将其导线接触到AAA电池的末端点燃。在小瓶内形成可见的气溶胶烟雾,并使其再次冷凝到壁上。高效液相色谱分析冷凝物显示,它由1.3mg纯烟碱组成。
实施例2:将药物涂布到铝基质上
高能闪光球形物(GE或Sylvania),可以产生300-400J的能量,将其插入一阳极化铝管中。将该闪光球形物/管组件浸泡到含有药物的有机溶液中并快速取出。通过将该组件放置在一真空室中持续30分钟从而将组件中的残余溶剂蒸发。这样在铝管外表面上留下一层涂布的药物薄膜。使用铜线将该闪光球形物组件电连接到两个1.5V电池和一个开关上,然后将其密封于一密封的玻璃小瓶中。通过即刻打开闪光球形物与电池之间的开关使闪光球形物点燃。点燃之后,将小瓶保持密封持续30分钟,以便挥发的药物颗粒聚集并冷凝到小瓶的内表面上。气溶胶的分析包括用5mL乙腈冲洗小瓶并将有机溶液的样品注入高效液相色谱设备中。用快速热电偶测定显示,铝管在50毫秒中加热至600℃。将其转化成加热速率为12000°/s。
本领域普通技术人员将理解的是,上面详细描述的试验设备,可以通过剔除密封小瓶并包括外壳以装入该组件和电子元件,从而转变成一吸入递送设备。该外壳将包括空气入口和接口,这样当药物挥发时,吸入的空气将载有形成的气溶胶到对象的肺中。
为了描述和说明的目的,前面已描述了本发明的具体实施方式。它们不打算详尽地或者限制本发明到公开的这些精确形式中,应理解的是可以根据上面的教导进行许多改进和改变。选择和描述这些实施方式是为了最好地解释本发明的原理及其实际应用,由此本领域的其它技术人员能够最好地利用本发明,并且包括适合实际应用的各种改进的不同实施方式。许多其它改变液应认为在本发明的范围内。
Claims (15)
1.一种蒸发药物(15)的方法,包括:
提供具有中部和接口(34)的外壳(30),其特征在于包括:在所述外壳(30)内的基质(20),该基质有包围内部区域的内表面(20a)和外表面(20b);其中所述药物(15)被涂布在所述基质(20)的外表面(20b)上,或浸渍在基质(20)中;其中将易燃成分(16)放置在所述基质(20)的内部;并且点火器与易燃成分相连;和
在所述基质(20)的内部区域引发放热反应,从而所述基质(20)的外表面(20b)被迅速加热并且药物(15)被蒸发到所述外壳(30)的中部。
2.权利要求1的方法,其中将易燃成分(16)密封在球形物(14)中。
3.权利要求2的方法,其中所述球形物(14)由玻璃制成。
4.权利要求3的方法,其中所述球形物(14)构成所述基质(20)的内表面和外表面。
5.权利要求1的方法,其中所述基质(20)是金属的。
6.如权利要求5的方法,其中所述基质(20)由不锈钢或铝形成。
7.如权利要求1的方法,其中所述易燃成分(16)在燃烧时消耗气体。
8.如权利要求7的方法,其中所述易燃成分(15)包括易燃金属。
9.如权利要求8的方法,其中所述易燃金属选自镁、锆或铝。
10.如权利要求2的方法,其中所述基质(20)被涂布到密封的球形物(14)上。
11.如权利要求1的方法,其中点火器是火花或电阻点火器并引发易燃成分(16)的燃烧。
12.如权利要求11的方法,其中所述点火器包括用于引发易燃成分(16)燃烧的电源(40),并且其中外壳(30)的远端部分(30a)容纳电源(40),外壳(30)的近端部分(30b)容纳基质(20)、易燃成分(16)和药物(15)。
13.如权利要求1的方法,其中所述方法包括在药物蒸发之后将蒸汽冷却并凝结蒸汽以提供气溶胶。
14.如权利要求1-13任一项的方法,其中所述药物(15)为纯的活性化合物形式。
15.如权利要求1-13任一项的方法,其中所述药物(15)为活性化合物和药用可接受的赋形剂的混合物的形式,且所述药用可接受的赋形剂是挥发性的或非挥发性的。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/146,086 US7458374B2 (en) | 2002-05-13 | 2002-05-13 | Method and apparatus for vaporizing a compound |
| US10/146,086 | 2002-05-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038141566A Division CN100540080C (zh) | 2002-05-13 | 2003-05-13 | 蒸发化合物的方法和装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101623528A CN101623528A (zh) | 2010-01-13 |
| CN101623528B true CN101623528B (zh) | 2012-03-07 |
Family
ID=29400465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101667825A Expired - Fee Related CN101623528B (zh) | 2002-05-13 | 2003-05-13 | 蒸发化合物的方法和装置 |
| CNB038141566A Expired - Fee Related CN100540080C (zh) | 2002-05-13 | 2003-05-13 | 蒸发化合物的方法和装置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038141566A Expired - Fee Related CN100540080C (zh) | 2002-05-13 | 2003-05-13 | 蒸发化合物的方法和装置 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7458374B2 (zh) |
| EP (3) | EP2052753B1 (zh) |
| JP (1) | JP4426439B2 (zh) |
| CN (2) | CN101623528B (zh) |
| AT (1) | ATE425784T1 (zh) |
| CA (1) | CA2485721C (zh) |
| CY (1) | CY1118820T1 (zh) |
| DE (1) | DE60326713D1 (zh) |
| DK (1) | DK2052753T3 (zh) |
| ES (2) | ES2323418T3 (zh) |
| HK (1) | HK1243014A1 (zh) |
| IL (1) | IL165161A0 (zh) |
| MX (1) | MXPA04011279A (zh) |
| PT (1) | PT2052753T (zh) |
| SI (1) | SI2052753T1 (zh) |
| WO (1) | WO2003095012A1 (zh) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| CA2447519C (en) | 2001-05-24 | 2008-09-16 | Alexza Molecular Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
| WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
| CA2460343A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
| WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
| PT1567164E (pt) | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor |
| US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| JP2007516404A (ja) | 2003-05-21 | 2007-06-21 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット |
| NL1025556C1 (nl) * | 2004-02-24 | 2005-08-26 | Jacob Korevaar | Inrichting en werkwijze voor het toedienen van een fluïdum aan een mens of zoogdier. |
| US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| US7826726B2 (en) * | 2004-06-07 | 2010-11-02 | Mccoy Mark S | Intra-convertible thermal vapor extraction and delivery system |
| EP2246086A3 (en) * | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
| CA2576906A1 (en) * | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Inhalation actuated percussive ignition system |
| US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
| JP4922934B2 (ja) * | 2004-08-12 | 2012-04-25 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 衝撃作動ヒートパッケージを組み込んだエアロゾル薬剤送達デバイス |
| JP2008520292A (ja) * | 2004-11-22 | 2008-06-19 | ベルナー,ヨハネス | 使い捨て吸入器 |
| US20160345631A1 (en) | 2005-07-19 | 2016-12-01 | James Monsees | Portable devices for generating an inhalable vapor |
| WO2007079118A1 (en) | 2005-12-29 | 2007-07-12 | Molex Incorporated | Heating element connector assembly with press-fit terminals |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US20080299048A1 (en) * | 2006-12-22 | 2008-12-04 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositions |
| US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
| US7840122B1 (en) | 2007-01-19 | 2010-11-23 | IntriMed Technologies, Inc. | Medicine vaporizer with crimped conductive pins |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| CN104645329A (zh) | 2007-11-30 | 2015-05-27 | Abbvie公司 | 蛋白制剂及其制备方法 |
| EP2110034A1 (en) | 2008-04-17 | 2009-10-21 | Philip Morris Products S.A. | An electrically heated smoking system |
| EP2113178A1 (en) | 2008-04-30 | 2009-11-04 | Philip Morris Products S.A. | An electrically heated smoking system having a liquid storage portion |
| DE102008030548B4 (de) * | 2008-06-27 | 2019-07-04 | Olig Ag | Rauchfreie Zigarette |
| EP2191735B1 (de) * | 2008-11-28 | 2011-04-13 | Olig AG | Rauchfreie Zigarette |
| DE102008030549A1 (de) * | 2008-06-27 | 2009-12-31 | Olig Ag | Rauchfreie Zigarette |
| US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| US8548623B2 (en) | 2009-03-18 | 2013-10-01 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| EP2253233A1 (en) | 2009-05-21 | 2010-11-24 | Philip Morris Products S.A. | An electrically heated smoking system |
| EP2319334A1 (en) | 2009-10-27 | 2011-05-11 | Philip Morris Products S.A. | A smoking system having a liquid storage portion |
| EP2327318A1 (en) | 2009-11-27 | 2011-06-01 | Philip Morris Products S.A. | An electrically heated smoking system with internal or external heater |
| US11247003B2 (en) * | 2010-08-23 | 2022-02-15 | Darren Rubin | Systems and methods of aerosol delivery with airflow regulation |
| US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
| ES2842407T3 (es) | 2010-12-22 | 2021-07-14 | Syqe Medical Ltd | Sistema de administración de fármacos |
| US9149586B2 (en) * | 2011-02-07 | 2015-10-06 | Seibo Ping-Cheng SHEN | Herbal vaporization apparatus and method |
| US20120325228A1 (en) * | 2011-06-23 | 2012-12-27 | Williams Jonnie R | Alkaloid composition for e-cigarette |
| AU2012306504B2 (en) | 2011-09-06 | 2015-08-20 | Nicoventures Trading Limited | Heating smokeable material |
| WO2013102609A2 (en) | 2012-01-03 | 2013-07-11 | Philip Morris Products S.A. | An aerosol generating device and system with improved airflow |
| US9282772B2 (en) | 2012-01-31 | 2016-03-15 | Altria Client Services Llc | Electronic vaping device |
| US20150010527A1 (en) | 2012-02-01 | 2015-01-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
| EP3473119A1 (en) | 2012-02-22 | 2019-04-24 | Altria Client Services LLC | Electronic smoking article and improved heater element |
| CA2864832A1 (en) | 2012-02-22 | 2013-08-29 | Altria Client Services Inc. | Electronic smoking article |
| US20150174158A1 (en) | 2012-03-07 | 2015-06-25 | Advanced Inhalation Therapies (Ait) Ltd. | Inhalation of nitric oxide for treating respiratory diseases |
| US10111461B2 (en) * | 2012-09-10 | 2018-10-30 | Healthier Choices Management Corp | Electronic vaping material container |
| GB201217067D0 (en) | 2012-09-25 | 2012-11-07 | British American Tobacco Co | Heating smokable material |
| USD691765S1 (en) | 2013-01-14 | 2013-10-15 | Altria Client Services Inc. | Electronic smoking article |
| USD841231S1 (en) | 2013-01-14 | 2019-02-19 | Altria Client Services, Llc | Electronic vaping device mouthpiece |
| USD691766S1 (en) | 2013-01-14 | 2013-10-15 | Altria Client Services Inc. | Mouthpiece of a smoking article |
| USD695449S1 (en) | 2013-01-14 | 2013-12-10 | Altria Client Services Inc. | Electronic smoking article |
| USD849993S1 (en) | 2013-01-14 | 2019-05-28 | Altria Client Services | Electronic smoking article |
| US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
| US9591876B2 (en) * | 2013-04-23 | 2017-03-14 | Atmos Nation Llc | Electric vaporizer heating assembly with dual anodized heating compartments |
| GB201311620D0 (en) | 2013-06-28 | 2013-08-14 | British American Tobacco Co | Devices Comprising a Heat Source Material and Activation Chambers for the Same |
| CA2918145C (en) | 2013-07-11 | 2018-06-19 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
| US9848645B2 (en) | 2013-07-24 | 2017-12-26 | Sis Resources Ltd. | Cartomizer structure for automated assembly |
| BR302014001648S1 (pt) | 2013-10-14 | 2015-06-09 | Altria Client Services Inc | Configuração aplicada em artigo de fumo |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
| US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
| USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
| US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
| KR102256888B1 (ko) | 2013-12-23 | 2021-05-31 | 쥴 랩스, 인크. | 기화 디바이스 시스템 및 방법 |
| US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
| USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
| GB201500582D0 (en) | 2015-01-14 | 2015-02-25 | British American Tobacco Co | Apparatus for heating or cooling a material contained therein |
| BR112016030955B1 (pt) | 2014-06-30 | 2022-03-22 | Syqe Medical Ltd. | Dispositivo inalador |
| CN106573123B (zh) | 2014-06-30 | 2021-08-31 | Syqe医药有限公司 | 用于活性剂的肺部递送的方法、装置及系统 |
| JP6663867B2 (ja) | 2014-06-30 | 2020-03-13 | サイケ メディカル リミテッドSyqe Medical Ltd. | 吸入装置用の薬物用量カートリッジ |
| US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| WO2016001922A1 (en) | 2014-06-30 | 2016-01-07 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| IL294077A (en) | 2014-06-30 | 2022-08-01 | Syqe Medical Ltd | Method and device for vaporizing and inhaling substances |
| MA40890A (fr) * | 2014-11-07 | 2017-09-12 | S A S C Ag | Dispositif chauffant de cigarette électronique |
| PL3220755T3 (pl) * | 2014-11-21 | 2019-08-30 | Philip Morris Products S.A. | Wyrób do palenia zawierający palne węglowe źródło ciepła zapalające się pod wpływem tarcia |
| EP3821735B1 (en) | 2014-12-05 | 2024-11-20 | Juul Labs, Inc. | Calibrated dose control |
| BR112017013311B1 (pt) | 2014-12-23 | 2022-05-31 | Acelrx Pharmaceuticals, Inc | Aparelho para a dispensação de formas de dosagem via oral e transmucosal |
| HK1245822A1 (zh) | 2015-01-04 | 2018-08-31 | Protalix Ltd | 一种经修饰的dnase及其应用 |
| HUE064899T2 (hu) | 2015-03-11 | 2024-04-28 | Alexza Pharmaceuticals Inc | Antisztatikus anyagok használata a légcsatornában a termális aeroszol kondenzációs folyamat létrehozására |
| RU2717638C2 (ru) * | 2015-07-20 | 2020-03-24 | Медикал Дивелопментс Интернэшнл Лимитед | Ингаляторное устройство для ингаляционных жидкостей |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US20170055575A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| US20170119047A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
| US11806331B2 (en) | 2016-01-06 | 2023-11-07 | Syqe Medical Ltd. | Low dose therapeutic treatment |
| MX377347B (es) | 2016-02-11 | 2025-03-07 | Juul Labs Inc | Cartucho rellenable de vaporizador y metodo de relleno |
| EP3419443A4 (en) | 2016-02-11 | 2019-11-20 | Juul Labs, Inc. | SAFE MOUNTING OF CARTRIDGES FOR EVAPORATOR DEVICES |
| US10433580B2 (en) | 2016-03-03 | 2019-10-08 | Altria Client Services Llc | Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge |
| US10455863B2 (en) | 2016-03-03 | 2019-10-29 | Altria Client Services Llc | Cartridge for electronic vaping device |
| US10368580B2 (en) | 2016-03-08 | 2019-08-06 | Altria Client Services Llc | Combined cartridge for electronic vaping device |
| US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
| US20170258140A1 (en) | 2016-03-11 | 2017-09-14 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
| US10368581B2 (en) | 2016-03-11 | 2019-08-06 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
| US10357060B2 (en) | 2016-03-11 | 2019-07-23 | Altria Client Services Llc | E-vaping device cartridge holder |
| CN205648910U (zh) * | 2016-03-14 | 2016-10-19 | 深圳市合元科技有限公司 | 烟支加热装置及其加热组件 |
| USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
| USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
| USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
| PT3551189T (pt) | 2016-12-09 | 2024-01-22 | Alexza Pharmaceuticals Inc | Alprazolam para utilização no tratamento da epilepsia |
| US10292436B2 (en) | 2017-07-10 | 2019-05-21 | Arc Innovations, Inc. | Electronic smoking systems, devices, and methods |
| USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
| KR102852740B1 (ko) | 2018-02-02 | 2025-08-29 | 알렉스자 파마스티칼즈, 인크. | 전기적 응축 에어로졸 디바이스 |
| IL277067B2 (en) * | 2018-03-14 | 2024-04-01 | Philip Morris Products Sa | Aerosol-generating system with biosensor |
| US11413409B2 (en) | 2018-09-12 | 2022-08-16 | Juul Labs, Inc. | Vaporizer including positive temperature coefficient of resistivity (PTCR) heating element |
| JP7638863B2 (ja) | 2018-11-05 | 2025-03-04 | ジュール・ラブズ・インコーポレイテッド | 気化器デバイス用のカートリッジ |
| JP7494170B2 (ja) | 2018-11-05 | 2024-06-03 | ジュール・ラブズ・インコーポレイテッド | 気化器デバイス用のカートリッジ |
| WO2020127225A1 (en) | 2018-12-17 | 2020-06-25 | Philip Morris Products S.A. | 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof |
| US20220071958A1 (en) | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| CN110432548B (zh) * | 2019-06-12 | 2024-09-10 | 深圳市合元科技有限公司 | 气溶胶生成系统 |
| WO2021046157A1 (en) | 2019-09-03 | 2021-03-11 | Juul Labs, Inc. | Fuel cell powered vaporizer device |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| AU2023244452A1 (en) | 2022-03-27 | 2024-11-07 | GH Research Ireland Limited | Treatment of cognitive dysfunction |
| US12159183B2 (en) * | 2022-09-19 | 2024-12-03 | Loft Labs, Llc | Apparatus and method for unique indentification of an object using near-field communication (NFC) |
| IL322428A (en) | 2023-01-30 | 2025-09-01 | Gh Res Ireland Limited | 5-Methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in nursing mothers |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4045156A (en) * | 1974-12-23 | 1977-08-30 | Gte Sylvania Incorporated | Photoflash lamp |
| US4693868A (en) * | 1982-09-30 | 1987-09-15 | Dainihon Jochugiku Co., Ltd. | Thermal fumigator for drugs |
| CN2064238U (zh) * | 1990-01-13 | 1990-10-24 | 廖仲力 | 支气管哮喘治疗仪 |
| CN2076862U (zh) * | 1990-12-19 | 1991-05-15 | 范业铎 | 糖尿病和感冒熏疗机 |
| CN1055480A (zh) * | 1990-04-01 | 1991-10-23 | 方存云 | 拔灸器 |
| CN2091670U (zh) * | 1991-03-22 | 1992-01-01 | 张仲海 | 电子火罐 |
| US5099861A (en) * | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
| CN2238656Y (zh) * | 1995-03-14 | 1996-10-30 | 王玉琛 | 电加热气化药水呼吸治疗器 |
| CN2306779Y (zh) * | 1997-03-11 | 1999-02-10 | 卞玉华 | 手持式熏蒸按摩器 |
| CN2374174Y (zh) * | 1999-06-04 | 2000-04-19 | 张仁杰 | 安全火罐 |
Family Cites Families (526)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3080624A (en) * | 1963-03-12 | weber iii | ||
| US2243669A (en) * | 1941-05-27 | Electrical vaporizer | ||
| US515170A (en) * | 1894-02-20 | Automatic toll-box for telephone pay-stations | ||
| US1864980A (en) * | 1932-06-28 | Vapobizeb | ||
| US1803334A (en) * | 1931-05-05 | Ootthujp lehmann | ||
| US1239634A (en) | 1916-07-25 | 1917-09-11 | Frank J Stuart | Medical appliance. |
| US1535486A (en) * | 1922-08-28 | 1925-04-28 | James W Lundy | Electric-lamp bulb |
| US2086140A (en) | 1933-09-08 | 1937-07-06 | Silten Ernst | Automatic temperature regulated narcosis apparatus |
| US2084299A (en) | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
| US2230754A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
| US2230753A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
| GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
| US2309846A (en) * | 1941-03-06 | 1943-02-02 | Holm Einar Marius | Inhaler |
| FR921852A (fr) | 1945-12-06 | 1947-05-21 | Diffuseur de produits volatils | |
| US2469656A (en) * | 1946-04-19 | 1949-05-10 | Peter H Lienert | Vaporizer |
| US2714649A (en) * | 1952-11-25 | 1955-08-02 | Lyle H Critzer | Vaporizer |
| US2761055A (en) * | 1953-06-10 | 1956-08-28 | Malcome Van Ike | Lamp-heated vaporizer |
| US2741812A (en) * | 1954-02-15 | 1956-04-17 | Tellier Andre | Perfume dispenser |
| US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
| US2887106A (en) * | 1956-09-27 | 1959-05-19 | Robinson Joseph | Combined vaporizer and cover for medicament jar |
| US2898649A (en) * | 1956-11-19 | 1959-08-11 | Elaine T Cassidy | Perfume diffuser |
| US3371085A (en) | 1959-12-10 | 1968-02-27 | Hoffmann La Roche | 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones |
| US3043977A (en) * | 1960-03-30 | 1962-07-10 | Puritron Corp | Device and method for producing negative ions |
| US3474101A (en) * | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| GB903866A (en) | 1961-05-09 | 1962-08-22 | Dausse Lab | Therapeutic preparations containing 7-substituted theophylline derivatives |
| NL135583C (zh) * | 1961-10-10 | |||
| US3299185A (en) | 1962-09-27 | 1967-01-17 | Ube Nitto Kasei Co | Dyeable polyolefin fibers containing a binary copolymer of styrene and acrylonitrile |
| US3169095A (en) * | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
| BE629985A (zh) | 1962-11-29 | |||
| GB1063512A (en) | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
| US3282729A (en) | 1963-02-27 | 1966-11-01 | Union Carbide Corp | Barrier coated thermoplastic olefin polymer substrates |
| US3200819A (en) * | 1963-04-17 | 1965-08-17 | Herbert A Gilbert | Smokeless non-tobacco cigarette |
| NL298071A (zh) | 1963-06-04 | |||
| IL26896A (en) | 1966-01-19 | 1970-11-30 | Endo Lab | 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones |
| US3909463A (en) | 1968-11-29 | 1975-09-30 | Allied Chem | Grafted block copolymers of synthetic rubbers and polyolefins |
| US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
| US4008723A (en) | 1970-03-23 | 1977-02-22 | Imperial Chemical Industries Limited | Smoking mixture |
| US3831606A (en) | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
| US3749547A (en) * | 1971-09-09 | 1973-07-31 | Airco Inc | Flashlamp with improved combustible foil |
| US3847650A (en) * | 1971-09-09 | 1974-11-12 | Airco Inc | Flashlamp with improved combustion foil and method of making same |
| US4166087A (en) | 1971-11-22 | 1979-08-28 | Cline-Buckner, Inc. | Automatic intermittent vapor dispenser |
| US3701782A (en) | 1972-02-10 | 1972-10-31 | Upjohn Co | 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds |
| US3763347A (en) * | 1972-04-13 | 1973-10-02 | Ncr Co | Vaporous lamp |
| IE37524B1 (en) | 1972-04-20 | 1977-08-17 | Gallaher Ltd | Synthetic smoking product |
| USRE30285E (en) | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
| US3864326A (en) | 1972-05-22 | 1975-02-04 | Robert S Babington | Spraying devices, in particular nebulizing devices |
| GB1366041A (en) | 1972-07-21 | 1974-09-11 | Kodama Bros Co Ltd | Device for volatilizing insecticides and the like |
| US3773995A (en) | 1972-10-27 | 1973-11-20 | Westinghouse Electric Corp | Motor advanced spring charging pawl and ratchet mechanism with spring assist |
| US3949743A (en) | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
| US3930796A (en) * | 1973-09-13 | 1976-01-06 | Universal Oil Products Company | Catalytic fume control device |
| US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
| US3971377A (en) | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
| US3894040A (en) | 1974-09-16 | 1975-07-08 | American Home Prod | 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters |
| US4020379A (en) * | 1975-10-02 | 1977-04-26 | Eg&G, Inc. | Bulb-shaped flashtube with metal envelope |
| US4104210A (en) | 1975-12-17 | 1978-08-01 | Monsanto Company | Thermoplastic compositions of high unsaturation diene rubber and polyolefin resin |
| US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
| US4286604A (en) | 1976-10-05 | 1981-09-01 | Gallaher Limited | Smoking materials |
| US4079742A (en) | 1976-10-20 | 1978-03-21 | Philip Morris Incorporated | Process for the manufacture of synthetic smoking materials |
| US4160765A (en) | 1976-11-17 | 1979-07-10 | Smithkline Corporation | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4141369A (en) * | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
| US4184099A (en) * | 1977-04-27 | 1980-01-15 | International Flavors & Fragrances Inc. | Composition for slow release of volatile ingredients at _high temperature; and article comprising same |
| DE2752384A1 (de) | 1977-08-29 | 1979-03-15 | Simes | Pharmazeutisches praeparat auf der basis beklemmungsloesender mittel und hemmstoffe der beta-adrenergischen rezeptoren |
| SE7812207L (sv) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer |
| US4183912A (en) * | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
| JPS54120065A (en) | 1978-02-24 | 1979-09-18 | Osaka Takeshi | Stick for blind person |
| US4198200A (en) * | 1978-05-18 | 1980-04-15 | Lord Corporation | Damage-preventive coatings |
| US4284089A (en) | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
| US4276243A (en) | 1978-12-08 | 1981-06-30 | Western Electric Company, Inc. | Vapor delivery control system and method |
| US4280629A (en) | 1979-01-08 | 1981-07-28 | Anchor Brush Company, Inc. | Container for nail polish or the like |
| US4219031A (en) | 1979-03-05 | 1980-08-26 | Philip Morris Incorporated | Smoking product having core of fibrillar carbonized matter |
| US4229931A (en) | 1979-03-05 | 1980-10-28 | Deere & Company | Hydraulic height sensing system with cylinder by-pass |
| IL59407A (en) | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
| US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| US4251525A (en) | 1979-05-25 | 1981-02-17 | Smithkline Corporation | 3-Allyl-7,8-dihydroxy-6-halo-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives |
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4340072A (en) | 1979-11-16 | 1982-07-20 | Imperial Group Limited | Smokeable device |
| JPS5687036U (zh) | 1979-12-07 | 1981-07-13 | ||
| ATE3774T1 (de) | 1980-05-02 | 1983-06-15 | Schering Corporation | Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung. |
| US4391285A (en) | 1980-05-09 | 1983-07-05 | Philip Morris, Incorporated | Smoking article |
| US4347855A (en) | 1980-07-23 | 1982-09-07 | Philip Morris Incorporated | Method of making smoking articles |
| US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
| US4376767A (en) | 1981-01-02 | 1983-03-15 | Merck & Co., Inc. | Pyridylmethyl esters of selected bio-affecting carboxylic acids |
| US4346059A (en) * | 1981-03-03 | 1982-08-24 | Donald Spector | Aroma-generating lamp structure |
| DE3116951C2 (de) | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Vorrichtung zur Beimischung flüssiger Narkosemittel in das dem Patienten zuzuführende Atemgas |
| JPS5876038A (ja) | 1981-10-28 | 1983-05-09 | 高森 正之 | 殺虫剤や芳香剤の蒸発装置 |
| GB2122903B (en) | 1982-06-22 | 1986-11-05 | Masayuki Takamori | Vaporizers for vaporisable substances and support media for substances usable therewith |
| DE3224849A1 (de) | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Dampfinhaliergeraet |
| US4556539A (en) * | 1982-08-27 | 1985-12-03 | Donald Spector | Disc-playing aroma generator |
| US4508726A (en) * | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
| US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
| US4753758A (en) | 1983-05-19 | 1988-06-28 | Intertech Resources Inc. | Respiratory humidifier |
| US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
| US4523589A (en) | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
| DE3326089A1 (de) | 1983-07-20 | 1985-02-07 | Gödecke AG, 1000 Berlin | Zur inhalation bestimmte darreichungsform von calcium-antagonisten |
| DE3476197D1 (en) | 1983-08-01 | 1989-02-23 | Mclean Hospital Corp | Gaba esters and gaba analogue esters |
| US4588721A (en) | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
| ATE44470T1 (de) | 1983-11-08 | 1989-07-15 | Bunnell Life Systems Inc | Befeuchter, insbesondere fuer atmungshilfesysteme. |
| GB8405190D0 (en) | 1984-02-28 | 1984-04-04 | British Petroleum Co Plc | Thermoplastic elastomer composition |
| US4627963A (en) * | 1984-02-29 | 1986-12-09 | Lad Technology, Inc. | Heat activated dispenser and method of dispensing a vapor therefrom |
| US4683231A (en) | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4647428A (en) * | 1984-06-04 | 1987-03-03 | Gyulay Joseph M | Air freshener method |
| US4755508A (en) | 1984-06-26 | 1988-07-05 | Merck & Co., Inc. | Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin |
| US5020548A (en) | 1985-08-26 | 1991-06-04 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
| US5067499A (en) | 1984-09-14 | 1991-11-26 | R. J. Reynolds Tobacco Company | Smoking article |
| US4793365A (en) | 1984-09-14 | 1988-12-27 | R. J. Reynolds Tobacco Company | Smoking article |
| US4854331A (en) | 1984-09-14 | 1989-08-08 | R. J. Reynolds Tobacco Company | Smoking article |
| US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
| US4647433A (en) * | 1984-10-01 | 1987-03-03 | Donald Spector | Long-life aroma-generating capsule |
| CN1024996C (zh) | 1984-12-21 | 1994-06-15 | 美国J·R瑞诺兹烟草公司 | 吸烟制品 |
| GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| US5119834A (en) | 1985-04-15 | 1992-06-09 | R. J. Reynolds Tobacco Company | Smoking article with improved substrate |
| US4928714A (en) | 1985-04-15 | 1990-05-29 | R. J. Reynolds Tobacco Company | Smoking article with embedded substrate |
| DE3686025T2 (de) | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
| US4722334A (en) * | 1985-07-16 | 1988-02-02 | Transpirator Technologies, Inc. | Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals |
| US4989619A (en) * | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
| US5105831A (en) * | 1985-10-23 | 1992-04-21 | R. J. Reynolds Tobacco Company | Smoking article with conductive aerosol chamber |
| US5060666A (en) | 1985-10-28 | 1991-10-29 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
| US5033483A (en) | 1985-10-28 | 1991-07-23 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
| US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
| US4793366A (en) | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
| JPS62204756A (ja) * | 1986-03-04 | 1987-09-09 | 大研医工株式会社 | 薬剤揮散方法および装置 |
| US4863720A (en) | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
| US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
| US4765347A (en) | 1986-05-09 | 1988-08-23 | R. J. Reynolds Tobacco Company | Aerosol flavor delivery system |
| US4771795A (en) | 1986-05-15 | 1988-09-20 | R. J. Reynolds Tobacco Company | Smoking article with dual burn rate fuel element |
| US4917120A (en) | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
| US4774971A (en) | 1986-06-03 | 1988-10-04 | Vieten Michael J | Cigarette substitute |
| US4801411A (en) | 1986-06-05 | 1989-01-31 | Southwest Research Institute | Method and apparatus for producing monosize ceramic particles |
| US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
| GB8622606D0 (en) | 1986-09-19 | 1986-10-22 | Imp Tobacco Ltd | Smoking article |
| US4856517A (en) | 1986-09-22 | 1989-08-15 | Collins Jason H | Umbilical cord clamp apparatus |
| US4858630A (en) | 1986-12-08 | 1989-08-22 | R. J. Reynolds Tobacco Company | Smoking article with improved aerosol forming substrate |
| IL84516A0 (en) | 1986-12-12 | 1988-04-29 | Reynolds Tobacco Co R | Smoking articles comprising impact modifying agents |
| US4734560A (en) * | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
| US4819665A (en) * | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
| US4968885A (en) | 1987-03-06 | 1990-11-06 | Extrel Corporation | Method and apparatus for introduction of liquid effluent into mass spectrometer and other gas-phase or particle detectors |
| US4924883A (en) | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
| HU201685B (en) | 1987-04-23 | 1990-12-28 | Chinoin Gyogyszer Es Vegyeszet | For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition |
| US4889850A (en) | 1987-05-11 | 1989-12-26 | Thornfeldt Carl R | Treatment of colic and teething |
| US5017575A (en) | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
| GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
| US5019122A (en) | 1987-08-21 | 1991-05-28 | R. J. Reynolds Tobacco Company | Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance |
| US4935624A (en) | 1987-09-30 | 1990-06-19 | Cornell Research Foundation, Inc. | Thermal-assisted electrospray interface (TAESI) for LC/MS |
| US5072726A (en) | 1987-10-09 | 1991-12-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Vaporizer for inhalation anesthetics during high-frequency jet ventilation and associated method |
| US4911157A (en) | 1988-01-07 | 1990-03-27 | Pegasus Research Corporation | Self-regulating, heated nebulizer system |
| US4906417A (en) * | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
| JPH01221313A (ja) | 1988-02-29 | 1989-09-04 | Hayashi Teruaki | 昇華放出薬剤組成物とその放出システム |
| US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5137034A (en) | 1988-05-16 | 1992-08-11 | R. J. Reynolds Tobacco Company | Smoking article with improved means for delivering flavorants |
| US4881556A (en) | 1988-06-06 | 1989-11-21 | R. J. Reynolds Tobacco Company | Low CO smoking article |
| US5264433A (en) | 1988-07-07 | 1993-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
| CH678151A5 (en) | 1988-07-13 | 1991-08-15 | Heinz Hermann Weick | Self-medication nasal dispenser |
| US5345951A (en) | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
| US4852561A (en) | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
| EP0358114A3 (en) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Aerosol delivery articles utilizing electrical energy |
| US4947874A (en) * | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
| US4947875A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
| US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
| USRE36744E (en) | 1988-09-16 | 2000-06-20 | Ribogene, Inc. | Nasal administration of benzodiazepine hypnotics |
| US4917830A (en) | 1988-09-19 | 1990-04-17 | The United States Of America As Represented By The United States Department Of Energy | Monodisperse aerosol generator |
| US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
| US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
| HU200105B (en) | 1988-10-04 | 1990-04-28 | Ferenc Inkovics | Electrically actuated inhaler of uniform medicine feeding |
| US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
| US4917119A (en) * | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| US4959380A (en) | 1988-12-19 | 1990-09-25 | Wilson Jordan E | Method of treating people to stop smoking and composition |
| US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
| GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
| US4892109A (en) * | 1989-03-08 | 1990-01-09 | Brown & Williamson Tobacco Corporation | Simulated smoking article |
| DE3908161A1 (de) | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Rauchbarer artikel |
| GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
| CA2058764A1 (en) | 1989-04-28 | 1990-10-29 | Peter D. Hodson | Dry powder inhalation device |
| CA2054197A1 (en) | 1989-05-05 | 1990-11-06 | Christopher O'neill | Fertility enhancement |
| US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
| US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
| US6313176B1 (en) | 1989-10-17 | 2001-11-06 | Everett J. Ellinwood, Jr. | Dosing method of administering deprenyl via intraoral administration or inhalation administration |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5269327A (en) | 1989-12-01 | 1993-12-14 | Philip Morris Incorporated | Electrical smoking article |
| US5408574A (en) * | 1989-12-01 | 1995-04-18 | Philip Morris Incorporated | Flat ceramic heater having discrete heating zones |
| US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
| US5224498A (en) | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
| US5093894A (en) * | 1989-12-01 | 1992-03-03 | Philip Morris Incorporated | Electrically-powered linear heating element |
| US5144962A (en) | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
| DE69031279T2 (de) | 1989-12-05 | 1998-03-19 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
| US5109180A (en) * | 1989-12-14 | 1992-04-28 | Phillips Petroleum Company | Apparatus providing a shatter-resistant electric lamp |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| GB2239807A (en) | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
| US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| US5156170A (en) | 1990-02-27 | 1992-10-20 | R. J. Reynolds Tobacco Company | Cigarette |
| US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5192548A (en) | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
| ATE156823T1 (de) | 1990-06-07 | 1997-08-15 | Zeneca Ltd | Therapeutische heterocyclische verbindungen |
| US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
| SE9002052D0 (sv) | 1990-06-08 | 1990-06-08 | Pharmacia Ab | Smoking composition |
| US5455043A (en) | 1990-06-13 | 1995-10-03 | Fischel-Ghodsian; Fariba | Device for controlled release of vaporous medications through nasal route |
| US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
| EP0469797B2 (en) | 1990-08-02 | 2001-12-12 | Datex-Ohmeda Inc. | Anaesthetic vaporiser |
| US5060667A (en) | 1990-08-16 | 1991-10-29 | Brown & Williamson Tobacco Corporation | Smoking article |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
| US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| NO904226D0 (no) | 1990-09-28 | 1990-09-28 | Forsvarets Forsknings | Fukteanordning. |
| US5179966A (en) * | 1990-11-19 | 1993-01-19 | Philip Morris Incorporated | Flavor generating article |
| US5095921A (en) * | 1990-11-19 | 1992-03-17 | Philip Morris Incorporated | Flavor generating article |
| HU219778B (hu) | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
| US5519019A (en) | 1990-12-21 | 1996-05-21 | Gyogyszerkutato Intezet | N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same |
| FR2671487B1 (fr) | 1991-01-14 | 1993-03-19 | Oreal | Utilisation d'un facteur de croissance dans une composition amincissante. |
| DE69229070T2 (de) | 1991-02-09 | 1999-11-18 | B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G., Bussero | Antireaktive antiasthmatische Wirkung von Acetylsalicylsäure durch Inhalation |
| US5394866A (en) | 1991-03-05 | 1995-03-07 | Aradigm Corporation | Automatic aerosol medication delivery system and methods |
| WO1994017370A2 (en) | 1991-03-05 | 1994-08-04 | Miris Medical Corporation | Method and device for correcting the drift offset of a pressure sensor of a flowmeter |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| US5226411A (en) | 1991-03-07 | 1993-07-13 | Walter Levine | Aerosol nebulizer heater |
| US5479948A (en) * | 1993-08-10 | 1996-01-02 | Philip Morris Incorporated | Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor |
| US5505214A (en) * | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
| US5249586A (en) | 1991-03-11 | 1993-10-05 | Philip Morris Incorporated | Electrical smoking |
| US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
| US5938117A (en) | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
| GB9109021D0 (en) | 1991-04-26 | 1991-06-12 | Boc Group Plc | Dosing pump |
| GB9109442D0 (en) * | 1991-05-01 | 1991-06-26 | Volex Group Plc | Apparatus for emitting a chemical agent |
| US5160664A (en) | 1991-05-31 | 1992-11-03 | Msp Corporation | High output monodisperse aerosol generator |
| US5261424A (en) | 1991-05-31 | 1993-11-16 | Philip Morris Incorporated | Control device for flavor-generating article |
| US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5177071A (en) | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
| CA2069687A1 (en) * | 1991-06-28 | 1992-12-29 | Chandra Kumar Banerjee | Tobacco smoking article with electrochemical heat source |
| US5285798A (en) * | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
| EP0532194A1 (en) | 1991-09-10 | 1993-03-17 | Philip Morris Products Inc. | Thermally-regulated flavor generator |
| US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
| US5363842A (en) | 1991-12-20 | 1994-11-15 | Circadian, Inc. | Intelligent inhaler providing feedback to both patient and medical professional |
| US5265685A (en) | 1991-12-30 | 1993-11-30 | Dresser Industries, Inc. | Drill bit with improved insert cutter pattern |
| GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
| US5229120A (en) | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
| US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
| DK64592D0 (da) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
| US5391081A (en) | 1992-05-13 | 1995-02-21 | University Of Florida Research Foundation, Incorporated | Method and apparatus for simulating neuromuscular stimulation during medical surgery |
| US5584701A (en) | 1992-05-13 | 1996-12-17 | University Of Florida Research Foundation, Incorporated | Self regulating lung for simulated medical procedures |
| US5525329A (en) | 1992-05-21 | 1996-06-11 | The Johns Hopkins University | Inhibition of phosphodiesterase in olfactory mucosa |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| US5622944A (en) | 1992-06-12 | 1997-04-22 | Affymax Technologies N.V. | Testosterone prodrugs for improved drug delivery |
| AU660824B2 (en) | 1992-06-12 | 1995-07-06 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
| US5284133A (en) * | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
| US5322075A (en) | 1992-09-10 | 1994-06-21 | Philip Morris Incorporated | Heater for an electric flavor-generating article |
| US5613505A (en) * | 1992-09-11 | 1997-03-25 | Philip Morris Incorporated | Inductive heating systems for smoking articles |
| US5333106A (en) | 1992-10-09 | 1994-07-26 | Circadian, Inc. | Apparatus and visual display method for training in the power use of aerosol pharmaceutical inhalers |
| AU5358694A (en) | 1992-10-28 | 1994-05-24 | Charles A. Rosen | Method and devices for delivering drugs by inhalation |
| US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
| US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
| US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
| US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
| US5970973A (en) | 1993-01-29 | 1999-10-26 | Aradigm Corporation | Method of delivering insulin lispro |
| US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
| US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
| US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
| US5372148A (en) | 1993-02-24 | 1994-12-13 | Philip Morris Incorporated | Method and apparatus for controlling the supply of energy to a heating load in a smoking article |
| US5468936A (en) | 1993-03-23 | 1995-11-21 | Philip Morris Incorporated | Heater having a multiple-layer ceramic substrate and method of fabrication |
| GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| WO1994028959A1 (de) | 1993-06-03 | 1994-12-22 | Barthold Von Schrader | Inhalationseinrichtung |
| US5666977A (en) | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
| DK0706352T3 (da) | 1993-06-29 | 2002-07-15 | Ponwell Entpr Ltd | Dispenser |
| US5388574A (en) | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
| DE4328243C1 (de) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Rauch- oder Inhalationsvorrichtung |
| US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
| US5462740A (en) | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
| US5400969A (en) * | 1993-09-20 | 1995-03-28 | Keene; Christopher M. | Liquid vaporizer and diffuser |
| SE9303574D0 (sv) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
| FI98270C (fi) | 1993-11-29 | 1997-05-26 | Instrumentarium Oy | Menetelmä ja sovitelma anesteetin höyrystämisen yhteydessä |
| MA23420A1 (fr) | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US5522008A (en) | 1994-03-16 | 1996-05-28 | Bernard; Costello J. | Device for heating and vaporizing a vaporizable module |
| US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
| MX9604393A (es) | 1994-03-30 | 1997-07-31 | Procter & Gamble | Composicion combinada de humectante y barra limpiadora para la piel. |
| US6102036A (en) | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
| CA2189351C (en) | 1994-05-13 | 2008-12-30 | Stephen J. Farr | Narcotic containing aerosol formulation |
| US5457101A (en) | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| MA23588A1 (fr) | 1994-06-23 | 1995-12-31 | Procter & Gamble | Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme |
| AU2702795A (en) | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration |
| MA23587A1 (fr) | 1994-06-23 | 1995-12-31 | Procter & Gamble | Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme |
| CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US6008214A (en) | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
| US5456677A (en) | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5537507A (en) | 1994-09-28 | 1996-07-16 | Advanced Ceramics Corporation | Coated flash evaporator heater |
| WO1996010663A1 (en) | 1994-09-30 | 1996-04-11 | M & J Fibretech A/S | A plant and a process for dry-producing a web-formed product |
| ES2171196T3 (es) | 1994-10-14 | 2002-09-01 | Glaxosmithkline Spa | Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño. |
| CA2202884C (en) | 1994-10-28 | 2009-01-06 | Lester J. Lloyd | Device and method of creating aerosolized mist of respiratory drug |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| US5540959A (en) | 1995-02-21 | 1996-07-30 | Howard J. Greenwald | Process for preparing a coated substrate |
| EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| DE19507410C2 (de) | 1995-03-03 | 1997-05-22 | Gsf Forschungszentrum Umwelt | Verfahren und Vorrichtung zur Herstellung von Aerosolen |
| US5565148A (en) | 1995-03-16 | 1996-10-15 | Minnesota Mining And Manufacturing Company | Device for selectively providing a multiplicity of aromas |
| AU5710896A (en) | 1995-03-31 | 1996-10-16 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
| US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
| US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
| US6014970A (en) * | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| EA000889B1 (ru) | 1995-04-14 | 2000-06-26 | Глаксо Веллкам Инк. | Дозирующий ингалятор дипропионата беклометазона |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| EE03997B1 (et) | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterooli doseeriv inhalaator |
| BR9604977A (pt) | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Inalador de dose medida sistema inalador de dose medida e uso do mesmo |
| US5725756A (en) | 1995-04-18 | 1998-03-10 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts with supercritical reaction media |
| US5690809A (en) | 1995-04-18 | 1997-11-25 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts by pretreatment of hydrocarbon feed to reduce peroxides and oxygen impurities |
| US5776928A (en) | 1995-04-21 | 1998-07-07 | Eli Lilly And Company | Method for treating dyskinesias with olanzapine |
| FR2733594B1 (fr) | 1995-04-28 | 1997-06-06 | France Etat | Dispositif pour le prelevement de substances gazeuses, de liquides, d'aerosols ou meme de matieres pulverulents, en vue de leur analyse in situ |
| US5809997A (en) | 1995-05-18 | 1998-09-22 | Medtrac Technologies, Inc. | Electronic medication chronolog device |
| DE19519056A1 (de) | 1995-05-24 | 1997-01-16 | Klinge Co Chem Pharm Fab | Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| GB9512708D0 (en) | 1995-06-22 | 1995-08-23 | Reckitt & Colman Inc | Improvements in or relating to organic compounds |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
| US5591409A (en) * | 1995-08-15 | 1997-01-07 | Watkins; Carl J. | Providing aromas |
| SE9503141D0 (sv) | 1995-09-12 | 1995-09-12 | Siemens Elema Ab | Narkosapparat |
| US5649554A (en) | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
| US6013050A (en) | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
| WO1997016181A1 (en) | 1995-11-03 | 1997-05-09 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US5564442A (en) | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
| US6041777A (en) | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
| KR100450861B1 (ko) | 1995-12-14 | 2005-03-16 | 다이쇼 세이야꾸 가부시끼가이샤 | 에어로졸제제 |
| SE9504580L (sv) | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Förfarande vid förgasning av en narkosvätska och en förgasare |
| AU1335397A (en) | 1995-12-21 | 1997-07-17 | Eli Lilly And Company | Method for treating dermatitis |
| EP0955885A1 (en) | 1996-02-05 | 1999-11-17 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
| US5829436A (en) | 1996-02-05 | 1998-11-03 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| GB9604329D0 (en) | 1996-02-29 | 1996-05-01 | Ici Plc | Electrostatic spraying |
| AU709384B2 (en) | 1996-03-01 | 1999-08-26 | University Of Kansas, The | Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| CA2220768A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
| GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
| GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
| GB2312848B (en) | 1996-04-26 | 1999-11-17 | Bespak Plc | Controlled flow inhalers |
| EP0896525B1 (en) | 1996-04-29 | 2003-08-27 | Dura Pharmaceuticals, Inc. | Methods of dry powder inhalation |
| US5743251A (en) | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5929093A (en) | 1996-06-13 | 1999-07-27 | Mayo Foundation For Medical Education And Research | Bifunctional acetylcholinesterase reactivators |
| US6125853A (en) | 1996-06-17 | 2000-10-03 | Japan Tobacco, Inc. | Flavor generation device |
| GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
| US6089857A (en) | 1996-06-21 | 2000-07-18 | Japan Tobacco, Inc. | Heater for generating flavor and flavor generation appliance |
| AU3400797A (en) | 1996-06-27 | 1998-01-14 | Merck & Co., Inc. | A method for treating meniere's disease |
| AU3455297A (en) | 1996-07-11 | 1998-02-09 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
| US6004516A (en) | 1996-08-06 | 1999-12-21 | Illinois Institute Of Technology | Apparatus for generating odor upon electronic signal demand |
| US6325475B1 (en) | 1996-09-06 | 2001-12-04 | Microfab Technologies Inc. | Devices for presenting airborne materials to the nose |
| CA2267973C (en) | 1996-10-03 | 2006-12-19 | Dmitri Kirpotin | Hydrophilic microparticles and methods to prepare same |
| US5934289A (en) | 1996-10-22 | 1999-08-10 | Philip Morris Incorporated | Electronic smoking system |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US5878752A (en) * | 1996-11-25 | 1999-03-09 | Philip Morris Incorporated | Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses |
| US5744469A (en) | 1996-11-26 | 1998-04-28 | Eli Lilly And Company | Method for treating dermatitis |
| CA2222830C (en) * | 1996-12-02 | 2004-03-30 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
| AU741439B2 (en) | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| EP0954282B1 (en) | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6461591B1 (en) | 1997-02-05 | 2002-10-08 | Jago Research Ag | Medical aerosol formulations |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| US6051257A (en) * | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
| US6192882B1 (en) | 1997-02-24 | 2001-02-27 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
| US5829435A (en) | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
| US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
| US5769621A (en) | 1997-05-23 | 1998-06-23 | The Regents Of The University Of California | Laser ablation based fuel ignition |
| US5907075A (en) | 1997-06-11 | 1999-05-25 | The University Of Kansas | Solid acid supercritical alkylation reactions using carbon dioxide and/or other co-solvents |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5928520A (en) | 1997-07-16 | 1999-07-27 | Abanaki Corporation | Method and apparatus for extracting ground water contaiminants |
| KR100289448B1 (ko) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | 향미발생장치 |
| HUP9701284A3 (en) | 1997-07-24 | 2005-11-28 | Egyt Gyogyszervegyeszeti Gyar | Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system |
| US6090212A (en) | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
| US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
| US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
| US6138683A (en) | 1997-09-19 | 2000-10-31 | Thione International, Inc. | Smokeless tobacco products containing antioxidants |
| ES2205560T5 (es) | 1997-09-29 | 2013-04-16 | Novartis Ag | Preparaciones estabilizadas para usar en inhaladores de dosis medida |
| US6390453B1 (en) | 1997-10-22 | 2002-05-21 | Microfab Technologies, Inc. | Method and apparatus for delivery of fragrances and vapors to the nose |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| DK1049695T3 (da) | 1997-11-12 | 2002-05-13 | Bayer Ag | 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer |
| PL342045A1 (en) | 1998-01-27 | 2001-05-21 | American Cyanamid Co | 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases |
| US6044777A (en) | 1998-02-09 | 2000-04-04 | Walsh; Michael J. | Composite metal safe and method of making |
| US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
| US5996589A (en) * | 1998-03-03 | 1999-12-07 | Brown & Williamson Tobacco Corporation | Aerosol-delivery smoking article |
| EP1080720A4 (en) | 1998-03-05 | 2002-06-05 | Nippon Shinyaku Co Ltd | FAT EMULSIONS FOR INHALATIVE ADMINISTRATION |
| ATE303837T1 (de) | 1998-03-05 | 2005-09-15 | Zivena Inc | Lungendosiersystem |
| WO1999052519A2 (en) | 1998-04-14 | 1999-10-21 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| WO1999055362A1 (en) | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Spray dried formulations of igf-i |
| US20020086852A1 (en) | 1998-05-14 | 2002-07-04 | Cantor Jerome O. | Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
| GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
| EP1083951A4 (en) | 1998-06-12 | 2004-07-07 | Aradigm Corp | METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY |
| US6095153A (en) * | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| US6090403A (en) | 1998-08-17 | 2000-07-18 | Lectec Corporation | Inhalation therapy decongestant with foraminous carrier |
| WO2000019991A1 (en) | 1998-10-02 | 2000-04-13 | Battelle Memorial Institute | Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
| US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
| US6509005B1 (en) * | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
| US6255334B1 (en) | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| DE19854009C2 (de) * | 1998-11-12 | 2001-04-26 | Reemtsma H F & Ph | System zur Bereitstellung eines inhalierbaren Aerosols |
| CZ20011581A3 (cs) | 1998-11-12 | 2001-12-12 | Frank G. Pilkiewicz | Systém pro podávání bioaktivní sloučeniny inhalací |
| DE19854007C2 (de) | 1998-11-12 | 2001-05-17 | Reemtsma H F & Ph | System zur Bereitstellung eines inhalierbaren Aerosols |
| CA2347856C (en) | 1998-11-13 | 2009-02-17 | Jago Research Ag | Dry powder for inhalation |
| US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
| CA2349712C (en) | 1998-11-16 | 2008-03-25 | Aradigm Corporation | Method of fabricating porous membrane with unique pore structure for aerosolized delivery of drugs |
| US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
| JP3506618B2 (ja) * | 1998-11-18 | 2004-03-15 | ウシオ電機株式会社 | 黄色光放射用白熱電球 |
| ATE251447T1 (de) | 1998-12-11 | 2003-10-15 | Pharmachemie Bv | Pharmazeutische zubereitungen zur inhalation eines opioids |
| CN1636011A (zh) | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬 |
| AR022423A1 (es) | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento |
| PT1031347E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis |
| US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
| AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| US6591839B2 (en) | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
| US6053176A (en) * | 1999-02-23 | 2000-04-25 | Philip Morris Incorporated | Heater and method for efficiently generating an aerosol from an indexing substrate |
| WO2000051491A1 (en) | 1999-03-05 | 2000-09-08 | Battelle Memorial Institute | Method for safely and effectively administering a drug by inhalation |
| JP2002543092A (ja) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | 肺投与用インスリン結晶 |
| DE60007960T2 (de) | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
| CA2370853C (en) | 1999-05-03 | 2007-07-10 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| US6309986B1 (en) | 1999-05-07 | 2001-10-30 | S. C. Johnson & Son, Inc. | Mat for dispensing volatile materials |
| DE60024811T3 (de) | 1999-05-27 | 2010-01-07 | Acusphere, Inc., Watertown | Poröse arzneistoffmatrizen und deren herstellungsverfahren |
| JP2003501257A (ja) | 1999-06-11 | 2003-01-14 | アラディジム コーポレーション | エーロゾルを生成する方法 |
| US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| CA2378913C (en) | 1999-07-16 | 2010-02-23 | Aradigm Corporation | System for effecting smoke cessation |
| CA2381425A1 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| AU781380B2 (en) | 1999-09-07 | 2005-05-19 | Conjuchem Biotechnologies Inc. | Pulmonary delivery for bioconjugation |
| ES2275545T3 (es) | 1999-09-15 | 2007-06-16 | Aradigm Corporation | Estructuras porosas para aerosolizacion reducida. |
| NZ517575A (en) | 1999-09-30 | 2004-04-30 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
| DK1224174T3 (da) | 1999-10-15 | 2004-01-26 | Hoffmann La Roche | Benzodiazepinderivater |
| ES2343124T3 (es) | 1999-10-29 | 2010-07-23 | Novartis Ag | Composiciones de polvo seco con dispersabilidad mejorada. |
| AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10001035A1 (de) * | 2000-01-13 | 2001-07-26 | Bayer Ag | Wirkstoffchip mit integriertem Heizelement |
| EP1941868A3 (en) | 2000-02-28 | 2011-06-29 | PharmaKodex Limited | Improvements in or relating to the delivery of oral drugs |
| EP1265504B1 (en) * | 2000-03-23 | 2009-07-22 | Pmpi Llc | Electrical smoking system and method |
| US6632047B2 (en) | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
| JP2001299916A (ja) | 2000-04-18 | 2001-10-30 | Kao Corp | マスク型吸入器 |
| MY136453A (en) | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
| WO2001095903A1 (en) | 2000-06-15 | 2001-12-20 | Respiratorius Ab | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
| GB0015981D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| FR2812545B1 (fr) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
| US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020117175A1 (en) | 2000-10-27 | 2002-08-29 | Kottayil S. George | Thermal vaporizing device for drug delivery |
| US20030121906A1 (en) | 2000-11-29 | 2003-07-03 | Abbott Richard C. | Resistive heaters and uses thereof |
| US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
| US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
| US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
| US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
| US6701921B2 (en) * | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
| US6443152B1 (en) | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
| FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
| US6680668B2 (en) * | 2001-01-19 | 2004-01-20 | Vishay Intertechnology, Inc. | Fast heat rise resistor using resistive foil |
| US20020176841A1 (en) | 2001-03-19 | 2002-11-28 | Praecis Pharmaceuticals Inc. | Pharmaceutical formulations for sustained release |
| US20030004142A1 (en) | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7585493B2 (en) * | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
| WO2002094242A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
| US20030138508A1 (en) | 2001-12-18 | 2003-07-24 | Novack Gary D. | Method for administering an analgesic |
| US7645442B2 (en) * | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
| WO2002094234A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of opioids through an inhalation route |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| CA2447519C (en) | 2001-05-24 | 2008-09-16 | Alexza Molecular Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| EP1392260A2 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
| JP4680498B2 (ja) * | 2001-07-31 | 2011-05-11 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 蒸発した液体を発生するための方法及び装置 |
| US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
| US6648950B2 (en) * | 2001-10-15 | 2003-11-18 | Hewlett-Packard Development Company, L.P. | Electro-thermal odor-releasing inks and methods for releasing odors from the same |
| US6779520B2 (en) | 2001-10-30 | 2004-08-24 | Iep Pharmaceutical Devices Inc. | Breath actuated dry powder inhaler |
| GB0126150D0 (en) | 2001-10-31 | 2002-01-02 | Gw Pharma Ltd | A device method and resistive element for vaporising a substance |
| WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
| CA2462576A1 (en) | 2001-11-21 | 2003-06-03 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
| CA2460343A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
| US6681769B2 (en) * | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
| US20030106551A1 (en) | 2001-12-06 | 2003-06-12 | Sprinkel F. Murphy | Resistive heater formed inside a fluid passage of a fluid vaporizing device |
| CN1176075C (zh) | 2001-12-07 | 2004-11-17 | 北京燕山石油化工公司研究院 | 吡咯衍生物的制备方法 |
| US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
| US6772756B2 (en) | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
| US6961515B2 (en) | 2002-02-15 | 2005-11-01 | Dekko Technologies, Inc. | PTC heater with flexible printed circuit board |
| US6728478B2 (en) | 2002-02-21 | 2004-04-27 | Dekko Heating Technologies, Inc. | Heated chemical delivery system |
| WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
| ES2300589T3 (es) * | 2002-06-06 | 2008-06-16 | S.C. JOHNSON & SON, INC. | Volatilizacion de superficie localizada. |
| US7040314B2 (en) | 2002-09-06 | 2006-05-09 | Philip Morris Usa Inc. | Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols |
| US6772757B2 (en) | 2002-10-25 | 2004-08-10 | Chrysalis Technologies Incorporated | Concentric controlled temperature profile fluid vaporizing device |
| CA2507158A1 (en) | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Treatment of headache with antipsychotics delivered by inhalation |
| PT1567164E (pt) | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Utilização de loxapina para o fabrico de um medicamento para o tratamento da dor |
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
| JP2007516404A (ja) | 2003-05-21 | 2007-06-21 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット |
| US20050037506A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
| JP4869927B2 (ja) * | 2003-08-04 | 2012-02-08 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 薬物送達デバイスのための基材および調製方法および使用 |
| JP2007526796A (ja) | 2003-12-15 | 2007-09-20 | アレックザ ファーマシューティカルズ, インコーポレイテッド | 薬剤エアロゾル吸入による突出痛の治療 |
| US20050131739A1 (en) | 2003-12-16 | 2005-06-16 | Alexza Molecular Delivery Corporation | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real time |
| US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| EP2246086A3 (en) * | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
| US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
| EP1809240A4 (en) | 2004-10-12 | 2010-06-16 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF A DRUG-FREE DRUG WITHOUT DANGER TO THE CARDIOVASCULAR SYSTEM |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
-
2002
- 2002-05-13 US US10/146,086 patent/US7458374B2/en not_active Expired - Lifetime
-
2003
- 2003-05-13 MX MXPA04011279A patent/MXPA04011279A/es active IP Right Grant
- 2003-05-13 ES ES03734014T patent/ES2323418T3/es not_active Expired - Lifetime
- 2003-05-13 EP EP09002094.2A patent/EP2052753B1/en not_active Expired - Lifetime
- 2003-05-13 CA CA2485721A patent/CA2485721C/en not_active Expired - Fee Related
- 2003-05-13 SI SI200332520A patent/SI2052753T1/sl unknown
- 2003-05-13 DK DK09002094.2T patent/DK2052753T3/en active
- 2003-05-13 CN CN2009101667825A patent/CN101623528B/zh not_active Expired - Fee Related
- 2003-05-13 DE DE60326713T patent/DE60326713D1/de not_active Expired - Lifetime
- 2003-05-13 EP EP16204982.9A patent/EP3207954A1/en not_active Withdrawn
- 2003-05-13 PT PT90020942T patent/PT2052753T/pt unknown
- 2003-05-13 AT AT03734014T patent/ATE425784T1/de active
- 2003-05-13 ES ES09002094.2T patent/ES2623467T3/es not_active Expired - Lifetime
- 2003-05-13 JP JP2004503091A patent/JP4426439B2/ja not_active Expired - Fee Related
- 2003-05-13 CN CNB038141566A patent/CN100540080C/zh not_active Expired - Fee Related
- 2003-05-13 WO PCT/US2003/014983 patent/WO2003095012A1/en not_active Ceased
- 2003-05-13 EP EP03734014A patent/EP1506031B1/en not_active Expired - Lifetime
-
2004
- 2004-11-11 IL IL16516104A patent/IL165161A0/xx unknown
-
2008
- 2008-11-21 US US12/275,836 patent/US7987846B2/en not_active Expired - Fee Related
-
2017
- 2017-04-07 CY CY20171100423T patent/CY1118820T1/el unknown
-
2018
- 2018-02-22 HK HK18102587.5A patent/HK1243014A1/zh unknown
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4045156A (en) * | 1974-12-23 | 1977-08-30 | Gte Sylvania Incorporated | Photoflash lamp |
| US4693868A (en) * | 1982-09-30 | 1987-09-15 | Dainihon Jochugiku Co., Ltd. | Thermal fumigator for drugs |
| CN2064238U (zh) * | 1990-01-13 | 1990-10-24 | 廖仲力 | 支气管哮喘治疗仪 |
| US5099861A (en) * | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
| CN1055480A (zh) * | 1990-04-01 | 1991-10-23 | 方存云 | 拔灸器 |
| CN2076862U (zh) * | 1990-12-19 | 1991-05-15 | 范业铎 | 糖尿病和感冒熏疗机 |
| CN2091670U (zh) * | 1991-03-22 | 1992-01-01 | 张仲海 | 电子火罐 |
| CN2238656Y (zh) * | 1995-03-14 | 1996-10-30 | 王玉琛 | 电加热气化药水呼吸治疗器 |
| CN2306779Y (zh) * | 1997-03-11 | 1999-02-10 | 卞玉华 | 手持式熏蒸按摩器 |
| CN2374174Y (zh) * | 1999-06-04 | 2000-04-19 | 张仁杰 | 安全火罐 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005525178A (ja) | 2005-08-25 |
| US20090071477A1 (en) | 2009-03-19 |
| EP2052753B1 (en) | 2017-01-25 |
| HK1129077A1 (zh) | 2009-11-20 |
| HK1243014A1 (zh) | 2018-07-06 |
| ES2323418T3 (es) | 2009-07-15 |
| CA2485721C (en) | 2011-07-26 |
| DK2052753T3 (en) | 2017-04-24 |
| WO2003095012A1 (en) | 2003-11-20 |
| EP1506031B1 (en) | 2009-03-18 |
| CN100540080C (zh) | 2009-09-16 |
| US20030209240A1 (en) | 2003-11-13 |
| ES2623467T3 (es) | 2017-07-11 |
| US7987846B2 (en) | 2011-08-02 |
| PT2052753T (pt) | 2017-04-11 |
| US7458374B2 (en) | 2008-12-02 |
| CY1118820T1 (el) | 2018-01-10 |
| ATE425784T1 (de) | 2009-04-15 |
| DE60326713D1 (de) | 2009-04-30 |
| CN1662272A (zh) | 2005-08-31 |
| CN101623528A (zh) | 2010-01-13 |
| MXPA04011279A (es) | 2005-02-17 |
| SI2052753T1 (sl) | 2017-05-31 |
| IL165161A0 (en) | 2005-12-18 |
| EP3207954A1 (en) | 2017-08-23 |
| EP1506031A1 (en) | 2005-02-16 |
| JP4426439B2 (ja) | 2010-03-03 |
| AU2003239441A1 (en) | 2003-11-11 |
| CA2485721A1 (en) | 2003-11-20 |
| WO2003095012B1 (en) | 2004-03-04 |
| HK1081888A1 (zh) | 2006-05-26 |
| EP2052753A1 (en) | 2009-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101623528B (zh) | 蒸发化合物的方法和装置 | |
| JP4601619B2 (ja) | 内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット | |
| TWI697288B (zh) | 匣體、構成為容納匣體的裝置、氣溶膠分送系統、分送氣溶膠化之含藥劑粒子給使用者的方法 | |
| JP2023134852A (ja) | サーマルエアゾール凝縮プロセスのためのエアウェイにおける帯電防止材の使用 | |
| EA034534B1 (ru) | Устройство, генерирующее аэрозоль, и капсула для использования в устройстве, генерирующем аэрозоль | |
| US20030131843A1 (en) | Open-celled substrates for drug delivery | |
| US20130233312A1 (en) | Portable Sublimation Device | |
| JP2019514528A (ja) | 制御された薬剤気化のための方法および装置 | |
| HK1081888B (zh) | 蒸發化合物的方法和裝置 | |
| AU2003239441B2 (en) | Method and apparatus for vaporizing a compound | |
| HK1129077B (zh) | 用於汽化化合物的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120307 |